Huntington’s Disease Drugs Market Set To Grow To Over $800m In 2018

03 August 2018
Pharma

Visiongain has launched a new pharma report Global Huntington’s Disease Drugs Market Forecast 2018-2028: Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules

Huntington’s Disease is a progressive neurodegenerative disorder which can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia play an important role in coordinating movement while cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. Huntington’s Disease has a broad impact on a person's functional abilities and usually results in movement, cognitive and psychiatric disorders. The most affected brain region is the striatum.

People suffering from Huntington’s Disease usually develop symptoms in their 30s and 50s. But the disease can emerge earlier or later in life. When the disease develops before age 20, the condition is called juvenile Huntington’s Disease. An earlier emergence of the disease often results in a different set of symptoms and faster disease progression. Medications are available to help manage the symptoms of Huntington’s Disease, but treatments can't prevent the physical, mental and behavioural decline associated with the condition.

The lead Visiongain report analyst for this report commented; ““The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.

Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.
There is a huge potential to tap the Huntington’s Disease market owing to high clinical & economic burden, the current lack of success rate of therapies, increasing patient awareness and physician education about HD.””

The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. The report discusses products from leading companies in the market. Notable companies in the Huntington’s Disease market include Hoffmann-La Roche, H.Lundbeck, Teva Pharmaceutical Industries Prana Biotechnology, Sangamo Therapeutics Inc., Horizon Pharma, Omeros Corp. and Valeant Pharmaceuticals amongst others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever